The Observation Of Clinical Effect Of Nuanxin Capsule In The Treatment Of Dilated Cardiomyopathy

OBJECTIVEWe aim to study the therapeutic effect of Nuanxin Capsule in patients with dilated cardiomyopathy,and to evaluate the safety of Nuanxin Capsule in the treatment of dilated cardiomyopathy.The aim is to develop a new method and clinical treatment for dilated cardiomyopathy.MethodsThis study is a clinical randomized controlled experiment.The SPSS software program is used to generate random distribution results.According to the order in which 74 subjects were included,all subjects were randomly assigned to the treatment group or the control group.The control group used a simple conventional western medicine scheme.In addition to the conventional western medicine regimen,the treatment group was also taking Nuanxin Capsules(3 times a day,3 capsules each time),the observation period was 4 weeks,and the basic conditions were followed up at 0,2,and 4 weeks.Relevant inspections were performed at the 0th week and the 4th week of the group.Establish a database and perform t-test(paired t-test)based on changes in TCM syndrome scores,cardiac function rating,ejection fraction,NT-proBNP,left ventricular end-diastolic diameter,and quality of life scores before and after treatment And rank sum test(paired symbol rank sum test)analysis to evaluate the clinical efficacy of Nuanxin Capsule on dilated cardiomyopathy.By comparing the basic vital signs,blood routine,and liver and kidney function of patients before and after treatment,the safety of Nuanxin Capsule in the treatment of dilated cardiomyopathy was evaluated.ResultsBefore treatment(week 0 of enrollment),there was no significant difference in general baseline data such as age,gender,and clinical baseline data such as cardiac function classification and TCM syndrome scores between the two groups(P>0.05).Groups can be compared.The research results obtained before and after treatment are compared as follows:(1)The total scores of TCM syndromes before and after treatment in the two groups,and the Wilcoxon rank sum test between paired samples between the groups,the difference is statistically significant(P<0.01),indicating that after treatment The TCM syndrome scores of patients in both groups were reduced;the comparison between two groups used the Wilcoxon rank sum test(P<0.05),suggesting that the TCM syndrome scores of the treatment group decreased more than the control group.(2)The quality of life scores of the two groups before and after treatment showed a normal distribution with the same variance.The t test was used to compare the differences within the group with statistical significance(P<0.01),suggesting that the total quality of life of the patients in the control group and the treatment group The scores were significantly lower than before;there was a statistically significant difference between the groups(P<0.01),indicating that the quality of life score in the treatment group decreased more than in the control group.(3)The cardiac function ratings of the control group and the treatment group were analyzed before and after treatment.There were 28 cases effective in the treatment group and 20 cases effective in the control group.Comparing the total effective rates of the two groups,the difference was statistically significant(P<0.01),Suggesting that the total effective rate of the two groups is different,and the cardiac function of the treatment group is better.(4)Comparison of NT-proBNP,LVEDD,and LVEF between the two groups before and after treatment,the difference within the group was statistically significant(P<0.05);the difference between the groups was statistically significant(P<0.01),suggesting that whether in the control group Still in the treatment group,NT-proBNP,LVEDD,and LVEF improved in all patients,and the treatment effect in the treatment group was better than that in the control group.(5)Observation and comparison of ALT,AST,Cr,and eGFR before and after treatment in the treatment group and the control group,the differences were not statistically significant(P>0.05),suggesting that the liver function of the patients in the two groups before and after treatment There were no significant changes in kidney and renal function,suggesting that the medication is safe.ConclusionNuanxin Capsule can improve the cardiac function classification of patients with dilated cardiomyopathy,reduce the NT-proBNP level of patients,reduce the left ventricular end-diastolic diameter,increase the left ventricular ejection fraction,and alleviate clinical symptoms and improve the quality of life of patients.At the same time,Nuanxin Capsule has no damage to the liver and kidney function of patients with dilated cardiomyopathy,and the clinical treatment effect and safety analysis of the drug are considered safe and effective.